Analyst firms · Raymond James · BMRN

Raymond James BMRN price target and rating history

BioMarin Pharmaceutical Inc. (BMRN) · Health Care

Raymond James rates BioMarin Pharmaceutical Inc. (BMRN) Strong Buy with a $109 price target, as of its latest action on Oct 12, 2026. It has published 4 rating actions on BMRN since September 2023, including 1 upgrade and 0 downgrades. Across 9 firms with a BMRN price target in the last 12 months, the median target is $88. Raymond James's $109 is 24% above that.

Current rating
Strong Buy
Price target
$109
Median target, all firms
$88
Actions on BMRN
4

Raymond James price target on BMRN

$109$94$7920252026
Raymond James price target on BMRN, each point a stated target, October 2024 to October 2026.

Every Raymond James rating on BMRN

How other firms rate BMRN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSBuy$88Oct 15, 2026
Raymond JamesStrong Buy$109Oct 12, 2026
BMO Capital MarketsOutperform$98Aug 19, 2026
CitigroupBuy$75May 19, 2026
Goldman SachsNeutral$69May 11, 2026
Morgan StanleyOverweight$120Apr 27, 2026
BarclaysOverweight$80Jan 28, 2026
Canaccord GenuityBuy$98Jan 20, 2026
Leerink PartnersMarket Perform$60Dec 3, 2025

Questions about Raymond James and BMRN

What is Raymond James's price target for BMRN?
Raymond James's latest stated price target for BioMarin Pharmaceutical Inc. (BMRN) is $109, from its action on Oct 12, 2026.
What is Raymond James's rating on BMRN?
Raymond James rates BMRN Strong Buy, a bullish rating, as of Oct 12, 2026.
When did Raymond James last change its view on BMRN?
On Oct 12, 2026, Raymond James upgrades to Strong Buy from Outperform, price target $109.
How does Raymond James's BMRN target compare with other analysts?
Across 9 firms with a BMRN price target in the last 12 months, the median target is $88. Raymond James's $109 is 24% above that.

More BMRN rating histories

All Raymond James ratingsBMRN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.